Media stories about Pulse Biosciences (NASDAQ:PLSE) have trended somewhat positive on Sunday, according to Accern Sentiment Analysis. The research firm scores the sentiment of news coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Pulse Biosciences earned a news sentiment score of 0.06 on Accern’s scale. Accern also gave news stories about the company an impact score of 46.3346992480116 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.

Shares of Pulse Biosciences (PLSE) traded up 5.16% on Friday, hitting $22.40. The stock had a trading volume of 138,095 shares. The stock has a 50 day moving average of $28.47 and a 200 day moving average of $23.44. Pulse Biosciences has a 12-month low of $4.35 and a 12-month high of $39.50. The firm’s market cap is $318.80 million.

Pulse Biosciences (NASDAQ:PLSE) last announced its quarterly earnings data on Thursday, July 27th. The company reported ($0.43) earnings per share (EPS) for the quarter.

TRADEMARK VIOLATION NOTICE: “Somewhat Favorable News Coverage Somewhat Unlikely to Affect Pulse Biosciences (PLSE) Stock Price” was originally published by Watch List News and is owned by of Watch List News. If you are accessing this story on another website, it was illegally copied and republished in violation of United States and international copyright laws. The correct version of this story can be viewed at https://www.watchlistnews.com/somewhat-favorable-news-coverage-somewhat-unlikely-to-affect-pulse-biosciences-plse-stock-price/1483851.html.

In related news, Director Maky Zanganeh acquired 8,290 shares of Pulse Biosciences stock in a transaction dated Wednesday, August 2nd. The shares were acquired at an average cost of $25.15 per share, for a total transaction of $208,493.50. Following the completion of the purchase, the director now owns 287,225 shares in the company, valued at $7,223,708.75. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, major shareholder Robert W. Duggan acquired 34,728 shares of Pulse Biosciences stock in a transaction dated Monday, May 22nd. The stock was bought at an average price of $26.25 per share, for a total transaction of $911,610.00. Following the completion of the purchase, the insider now owns 3,054,244 shares of the company’s stock, valued at approximately $80,173,905. The disclosure for this purchase can be found here. Over the last quarter, insiders bought 433,186 shares of company stock worth $10,484,411. Insiders own 6.70% of the company’s stock.

About Pulse Biosciences

Pulse Biosciences, Inc, formerly Electroblate, Inc, is a development-stage medical device company using a platform technology called Nano-Pulse Electro-Signaling (NPES). NPES is a local and drug-free technology that utilizes nanosecond pulsed electric fields to induce cell signaling and the activation of cellular pathways in tissue.

Receive News & Ratings for Pulse Biosciences Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulse Biosciences Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.